The company has called the updated vaccine, which targets two strains of the coronavirus, its “lead candidate” for the fall.
— which is designed to target both the omicron variant and the original coronavirus strain in a single shot — led to an eightfold increase in neutralizing antibody levels, according to the company.
The new shot, called mRNA-1273.214, was tested in a Phase 2/3 clinical trial of 437 people at 50 micrograms — the same dosage given in the current booster shot.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: